非编码RNA调控铁死亡介导肝细胞癌索拉非尼耐药的研究进展

doi:10.11904/j.issn.1002-3070.2025.03.012

实用肿瘤学杂志 ›› 2025, Vol. 39 ›› Issue (3): 256-261.doi: 10.11904/j.issn.1002-3070.2025.03.012

非编码RNA调控铁死亡介导肝细胞癌索拉非尼耐药的研究进展

朱磊¹ 综述, 郝丹丹² 审校

1.赤峰学院附属医院检验科(赤峰 024005);
2赤峰学院医学部基础医学院生理学教研室

收稿日期:2024-08-09 修回日期:2025-04-02 出版日期:2025-06-28 发布日期:2025-07-02
通讯作者: 郝丹丹,E-mail:hdd2011yx@163.com
作者简介:朱磊,男,(1989—),学士,主管检验技师,从事发现肿瘤生物标志物的研究。
基金资助:
内蒙古自治区自然科学基金(编号:2022MS08032)

Research progress on non-coding RNAs in the regulation of ferroptosis mediated sorafenib resistance in hepatocellular carcinoma

ZHU Lei¹, HAO Dandan²

1. Department of Clinical Laboratory,The Affiliated Hospital of Chifeng University,Chifeng 024005,China;
2. Department of Physiology,Medical college,Chifeng University

Received:2024-08-09 Revised:2025-04-02 Online:2025-06-28 Published:2025-07-02

摘要/Abstract

摘要： 铁死亡是一种由铁离子介导的脂质过氧化驱动的非凋亡性细胞程序性死亡,与多种肿瘤的发生发展密切相关。近年来研究表明,非编码RNA(non-coding RNA,ncRNA)可通过调控铁死亡通路影响肿瘤耐药进程。本文总结了ncRNAs通过铁死亡调控肝细胞癌(hepatocellular carcinoma,HCC)索拉非尼(sorafenib)耐药的分子机制,重点阐述微RNA(microRNA,miRNA)、长链非编码RNA(long noncoding RNA,lncRNA)和环状RNA(circular RNA,circRNA)等不同亚型ncRNA在其中的调控作用。本文有助于深入解析ncRNA通过铁死亡途径介导HCC索拉非尼耐药的关键分子机制,同时为未来探索HCC新型诊断生物标志物及治疗靶点提供理论依据。

关键词: 肝细胞癌, 非编码RNA, 铁死亡, 索拉非尼, 生物标志物

Abstract: Ferroptosis is a non-apoptotic programmed cell death driven by iron ion-mediated lipid peroxidation,which is closely related to the occurrence and development of various tumors.In recent years,many studies have shown that non-coding RNA(ncRNA)can affect tumor drug resistance by regulating the ferroptosis pathway.This article summarizes the molecular mechanisms of ncRNAs regulating sorafenib resistance in hepatocellular carcinoma(HCC)through ferroptosis,with a focus on the regulatory roles of different ncRNA subtypes such as microRNA(miRNA),long noncoding RNA(lncRNA),and circular RNA(circRNA).The article not only contributes to a deeper analysis of the key molecular mechanisms by which ncRNA mediate sorafenib resistance in HCC through ferroptosis pathways,but also provides a theoretical basis for exploring novel diagnostic biomarkers and therapeutic targets for HCC in the future.

Key words: Hepatocellular carcinoma, Non-coding RNA, Ferroptosis, Sorafenib, Biomarkers

中图分类号:

R735.7

朱磊, 郝丹丹. 非编码RNA调控铁死亡介导肝细胞癌索拉非尼耐药的研究进展[J]. 实用肿瘤学杂志, 2025, 39(3): 256-261.

ZHU Lei, HAO Dandan. Research progress on non-coding RNAs in the regulation of ferroptosis mediated sorafenib resistance in hepatocellular carcinoma[J]. Journal of Practical Oncology, 2025, 39(3): 256-261.

参考文献

1 Yang JD,Hainaut P,Gores GJ,et al.A global view of hepatocellular carcinoma:trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
2 Wang Z,Zhou C,Zhang Y,et al.From synergy to resistance:navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma[J].Biomed Pharmacother,2024,170:116074.
3 Balihodzic A,Prinz F,Dengler MA,et al.Non-coding RNAs and ferroptosis:potential implications for cancer therapy[J].Cell Death Differ,2022,29(6):1094-1106.
4 Zuo YB,Zhang YF,Zhang R,et al.Ferroptosis in cancer progression:role of noncoding rnas[J].Int J Biol Sci,2022,18(5):1829-1843.
5 Stockwell BR.Ferroptosis turns 10:emerging mechanisms,physiological functions,and therapeutic applications[J].Cell,2022,185(14):2401-2421.
6 Lei G,Zhuang L,Gan B.Targeting ferroptosis as a vulnerability in cancer[J].Nat Rev Cancer,2022,22(7):381-396.
7 Chen X,Kang R,Kroemer G,et al.Ferroptosis in infection,inflammation,and immunity[J].J Exp Med,2021,218(6):e20210518.
8 Hadian K,Stockwell BR.Snapshot:ferroptosis[J].Cell,2020,181(5):1188-1188.e1.
9 Jacquemyn J,Ralhan I,Ioannou MS.Driving factors of neuronal ferroptosis[J].Trends Cell Biol,2024,34(7):535-546.
10 Chen X,Yu C,Kang R,et al.Iron metabolism in ferroptosis[J].Front Cell Dev Biol,2020,8:590226.
11 David S,Jhelum P,Ryan F,et al.Dysregulation of iron homeostasis in the central nervous system and the role of ferroptosis in neurodegenerative disorders[J].Antioxid Redox Signal,2022,37(1-3):150-170.
12 Kagan VE,Mao G,Qu F,et al.Oxidized arachidonic and adrenic pes navigate cells to ferroptosis[J].Nat Chem Biol,2017,13(1):81-90.
13 Conrad M,Pratt DA.The chemical basis of ferroptosis[J].Nat Chem Biol,2019,15(12):1137-1147.
14 Dos Santos AF,Fazeli G,Xavier da Silva TN,et al.Ferroptosis:mechanisms and implications for cancer development and therapy response[J].Trends Cell Biol,2023,33(12):1062-1076.
15 Geng N,Shi BJ,Li SL,et al.Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells[J].Eur Rev Med Pharmacol Sci,2018,22(12):3826-3836.
16 Hou W,Xie Y,Song X,et al.Autophagy promotes ferroptosis by degradation of ferritin[J].Autophagy,2016,12(8):1425-1428.
17 Liang D,Minikes AM,Jiang X.Ferroptosis at the intersection of lipid metabolism and cellular signaling[J].Mol Cell,2022,82(12):2215-2227.
18 Bolton EM,Tuzova AV,Walsh AL,et al.Noncoding RNAs in prostate cancer:the long and the short of it[J].Clin Cancer Res,2014,20(1):35-43.
19 Wang Y,Hu J,Wu S,et al.Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases[J].Signal Transduct Target Ther,2023,8(1):449.
20 Yang M,Luo H,Yi X,et al.The epigenetic regulatory mechanisms of ferroptosis and its implications for biological processes and diseases[J].MedComm(2020),2023,4(3):e267.
21 Valashedi MR,Bamshad C,Najafi-Ghalehlou N,et al.Non-coding RNAs in ferroptotic cancer cell death pathway:meet the new masters[J].Hum Cell,2022,35(4):972-994.
22 Ensoy M,Bumin ZS,Jama HA,et al.The regulation role of ferroptosis mechanism of anti-cancer drugs and noncoding rnas[J].Curr Med Chem,2023,30(14):1638-1656.
23 Wang D,Tang L,Zhang Y,et al.Regulatory pathways and drugs associated with ferroptosis in tumors[J].Cell Death Dis,2022,13(6):544.
24 Sun J,Liu Q,Jiang Y,et al.Engineered small extracellular vesicles loaded with mir-654-5p promote ferroptosis by targeting hspb1 to alleviate sorafenib resistance in hepatocellular carcinoma[J].Cell Death Discov,2023,9(1):362.
25 Lu Y,Chan YT,Tan HY,et al.Epigenetic regulation of ferroptosis via ets1/mir-23a-3p/acsl4 axis mediates sorafenib resistance in human hepatocellular carcinoma[J].J Exp Clin Cancer Res,2022,41(1):3.
26 Zhao Y,Han S,Zeng Z,et al.Decreased lncRNA hnf4a-as1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism[J].Theranostics,2024,14(18):7088-7110.
27 Wang L,Wang L.Long noncoding RNA ddx11-as1 represses sorafenib-induced ferroptosis in hepatocellular carcinoma cells via nrf2-keap1 pathway[J].Discov Oncol,2024,15(1):544.
28 Shi CJ,Pang FX,Lei YH,et al.5-methylcytosine methylation of malat1 promotes resistance to sorafenib in hepatocellular carcinoma through elavl1/slc7a11-mediated ferroptosis[J].Drug Resist Updat,2025,78:101181.
29 Chen F,Wang L.Long noncoding RNA casc11 suppresses sorafenib-triggered ferroptosis via stabilizing slc7a11 mRNA in hepatocellular carcinoma cells[J].Discov Oncol,2023,14(1):145.
30 Gao Y,Tong M,Wong TL,et al.Long noncoding RNA urb1-antisense RNA 1(as1)suppresses sorafenib-induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation[J].ACS Nano,2023,17(22):22240-22258.
31 Shi Z,Li Z,Jin B,et al.Loss of lncRNA duxap8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via slc7a11 de-palmitoylation[J].Clin Transl Med,2023,13(6):e1300.
32 Li X,Li Y,Lian P,et al.Silencing lncRNA hcg18 regulates gpx4-inhibited ferroptosis by adsorbing mir-450b-5p to avert sorafenib resistance in hepatocellular carcinoma[J].Hum Exp Toxicol,2023,42:9603271221142818.
33 Jing F,Shi Y,Jiang D,et al.Circ_0001944 targets the mir-1292-5p/fbln2 axis to facilitate sorafenib resistance in hepatocellular carcinoma by impeding ferroptosis[J].Immunotargets Ther,2024,13:643-659.
34 Liu Z,Wang Q,Wang X,et al.Circular RNA cIARS regulates ferroptosis in HCC cells through interacting with RNA binding protein alkbh5[J].Cell Death Discov,2020,6:72.
35 Dong FL,Xu ZZ,Wang YQ,et al.Exosome-derived circupf2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma[J].J Nanobiotechnology,2024,22(1):298.

[1]	王心雨, 张奇. 基于生物学先验信息和基因调控网络筛选食管癌诊断及预后标志物[J]. 实用肿瘤学杂志, 2025, 39(3): 208-215.
[2]	李冬生, 李泽昊, 陈永刚. 铁死亡相关基因的DNA甲基化风险评分模型在结肠癌预后与免疫特征评估中的应用[J]. 实用肿瘤学杂志, 2025, 39(3): 224-234.
[3]	武旭, 德乐黑巴特尔, 达林泰, 苏尼特, 刘军. 长链非编码RNA在口腔鳞状细胞癌中的研究进展[J]. 实用肿瘤学杂志, 2025, 39(3): 251-255.
[4]	关勇宇, 聂昊, 张翀. 肝细胞癌小鼠模型构建的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 342-348.
[5]	程泳铭, 董欢欢, 徐晖. Hsa-let-7b-5p抑制非小细胞肺癌的增殖、迁移和侵袭[J]. 实用肿瘤学杂志, 2024, 38(3): 157-167.
[6]	周建云, 储巧香, 陆月梅, 朱静, 丁其培. lncRNA GAS5对宫颈癌细胞增殖、侵袭能力及PTEN/Akt/mTOR信号通路的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 96-103.
[7]	薄芸, 杭文璐, 左淑润, 董圆, 李海泉. 长链非编码RNA OTUD6B-AS1对肺腺癌A549细胞增殖、侵袭和迁移能力的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 13-17.
[8]	尚宏悦, 姚曼曼, 路月亭, 王迪娴, 赵乾, 刘铁军. lncRNA CASC2与肿瘤化疗耐药实验研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 67-70.
[9]	薛羽婷, 毛雄辉, 孙冀, 苑振楠. 长链非编码RNA LINC-PINT通过Hippo/YAP信号通路在缺氧诱导的头颈部鳞状细胞癌药物敏感性中的作用研究[J]. 实用肿瘤学杂志, 2023, 37(6): 466-471.
[10]	鲁亚杰, 王丽红. 蒽环类药物相关心脏毒性早期生物标志物研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 496-501.
[11]	庞武, 陈莉江, 朱宇, 吴涯昆, 张伟. 血清miRNA-24和miRNA-509在肝细胞癌患者血清中的表达及与预后的关系[J]. 实用肿瘤学杂志, 2023, 37(5): 411-415.
[12]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[13]	曹文源, 罗晓婷, 何倩. 外泌体miRNA在甲状腺癌淋巴结转移临床诊断中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 434-438.
[14]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.
[15]	隋世尧, 郑玮, 杨子涵, 庞达. lncRNA SNHG4通过EP300-SNHG4-GPX4轴抑制乳腺癌细胞铁死亡[J]. 实用肿瘤学杂志, 2023, 37(3): 215-223.

非编码RNA调控铁死亡介导肝细胞癌索拉非尼耐药的研究进展

Research progress on non-coding RNAs in the regulation of ferroptosis mediated sorafenib resistance in hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价